It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Biogen said it is charging $56,000 for an annual course of the new treatment, which was approved by the FDA on Monday.
“If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion” a year, the group said, “far surpassing spending on all other Part B-covered drugs combined.”
originally posted by: Chalcedony
a reply to: JIMC5499
Two members of the FDA advisory panel also resigned upon the accelerated approval of the new alzheimers drug from Biogen. They didn't think there was enough investigation into it's effectiveness do an accelerated approval for it. Biogen has come under fire previously for developing a drug for I think MD that cost 750,000 a year. This new alzheimers drug is cheaper. ...
originally posted by: carewemust
CNN must have been offered huge financial kickbacks from the pharmaceutical companies, because they are pushing this booster roll out date of September 20th, very very hard.